Nintedanib is an anti-fibrotic drug that suppressed CAFs expressing α-SMA and greatly reduced levels of ICC-promoting cytokines IL-6 and IL-8, secreted by CAFs. The gene discussed is ACTA1; the disease is intrahepatic cholangiocarcinoma.